Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium [177Lu] PSMA-0057 in PSMA-positive metastatic castration-resistant prostate cancer
CTR20254607Phase 2Active
- Sponsor
- Suzhou Ruihe Pharmaceutical Technology
- Start
- Dec 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu-177 PSMA-0057 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Suzhou Ruihe Pharmaceutical Technology. Started Dec 2025; status: active.
02
Drugs
lutetium Lu-177 PSMA-0057
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20254607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254607.